Biohaven Ltd (BHVN)

$53.09

-0.65

(-1.21%)

Market is closed - opens 8 PM, 08 Nov 2024

Performance

  • $53.09
    $54.66
    $53.09
    downward going graph

    0.0%

    Downside

    Day's Volatility :2.87%

    Upside

    2.87%

    downward going graph
  • $26.80
    $62.21
    $53.09
    downward going graph

    49.52%

    Downside

    52 Weeks Volatility :56.92%

    Upside

    14.66%

    downward going graph

Returns

PeriodBiohaven LtdIndex (Russel 2000)
3 Months
55.45%
0.0%
6 Months
29.59%
0.0%
1 Year
77.71%
0.0%
3 Years
-61.55%
-27.4%

Highlights

Market Capitalization
5.2B
Book Value
$4.16
Earnings Per Share (EPS)
-9.3
Wall Street Target Price
65.23
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-89.65%
Return On Equity TTM
-193.67%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-774.4M
Diluted Eps TTM
-9.3
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-8.88
EPS Estimate Next Year
-6.32
EPS Estimate Current Quarter
-1.77
EPS Estimate Next Quarter
-1.7

Analyst Recommendation

Buy
    94%Buy
    5%Hold
    0
    0%Sell
Based on 17 Wall street analysts offering stock ratings for Biohaven Ltd(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
16
16
14
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 22.87%

Current $53.09
Target $65.23

Technicals Summary

Sell

Neutral

Buy

Biohaven Ltd is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Biohaven Ltd
Biohaven Ltd
1.88%
29.59%
77.71%
-61.55%
16.8%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-18.01%
-15.81%
-1.7%
31.13%
150.21%
Biontech Se
Biontech Se
-12.27%
17.34%
4.17%
-56.04%
478.94%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
2.34%
76.9%
60.41%
45.24%
198.24%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
10.04%
20.33%
30.51%
156.8%
152.08%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Biohaven Ltd
Biohaven Ltd
NA
NA
NA
-8.88
-1.94
-0.9
NA
4.16
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
20.49
20.54
1.22
44.74
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-2.99
-0.03
-0.02
NA
85.17
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-1.87
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.27
0.19
-0.03
0.12
NA
60.66
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Biohaven Ltd
Biohaven Ltd
Buy
$5.1B
16.8%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$91.1B
150.21%
20.49
33.61%
Biontech Se
Biontech Se
Buy
$26.5B
478.94%
160.8
-18.75%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.8B
198.24%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$121.6B
152.08%
32.84
-4.51%

Insights on Biohaven Ltd

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 45.8% return, outperforming this stock by 109.0%

Institutional Holdings

  • Vanguard Group Inc

    7.20%
  • Stifel Financial Corp

    6.42%
  • BlackRock Inc

    6.11%
  • HHG PLC

    5.84%
  • Suvretta Capital Management, LLC

    5.15%
  • State Street Corp

    3.62%

Corporate Announcements

  • Biohaven Ltd Earnings

    Biohaven Ltd’s price-to-earnings ratio stands at None

    Read More

Company Information

Organization
Biohaven Ltd
Employees
239
CEO
Dr. Vladimir Coric M.D.
Industry
Health Technology

FAQs